Randomized Trial of Early mTOR Inhibition in Patients with Acute ST-Segment Elevation Myocardial Infarction.

Stähli, Barbara E; Klingenberg, Roland; Heg, Dik; Branca, Mattia; Manka, Robert; Kapos, Ioannis; Müggler, Oliver; Denegri, Andrea; Kesterke, Rahel; Berger, Florence; Stehli, Julia; Candreva, Alessandro; von Eckardstein, Arnold; Carballo, David; Hamm, Christian; Landmesser, Ulf; Mach, François; Moccetti, Tiziano; Jung, Christian; Kelm, Malte; ... (2022). Randomized Trial of Early mTOR Inhibition in Patients with Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 80(19), pp. 1802-1814. Elsevier 10.1016/j.jacc.2022.08.747

[img]
Preview
Text
1-s2.0-S073510972206613X-main.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (795kB) | Preview
[img] Text
St_hli_JAmCollCardiol_2022.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

BACKGROUND

Early inflammation following acute ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) affects myocardial infarct (MI) size and left ventricular remodeling. The mammalian target of rapamycin (mTOR) is involved in the enhanced inflammatory response and its inhibition has exerted beneficial effects on MI size in preclinical models of acute MI.

OBJECTIVES

The Controlled Level EVERolimus in Acute Coronary Syndromes trial (CLEVER-ACS) evaluated the effects of targeting inflammation by mTOR inhibition in patients with STEMI undergoing PCI.

METHODS

CLEVER-ACS was a randomized, multicenter, international, double-blind, placebo-controlled trial. A total of 150 patients with STEMI undergoing PCI were randomly assigned to oral everolimus (days 1-3: 7.5 mg qd, days 4-5: 5.0 mg qd) or placebo for 5 days. The primary endpoint was the change in myocardial infarct size, the secondary endpoint the change in microvascular obstruction (MVO) from baseline (12 hours - 5 days after PCI) to 30 days as assessed by cardiac magnetic resonance imaging (CMR).

RESULTS

The changes in MI size from baseline to 30 days, the primary endpoint, were -14.2 (95% CI -17.4 to -11.1) g and -12.3 (95% CI -16.0 to -8.7) g in the everolimus and placebo groups (p=0.99). Corresponding changes in MVO were -4.8 (-6.7 to -2.9) g and -6.3 (-8.7 to -4.0) g in the everolimus and placebo groups (p=0.14). Adverse events did not differ between the study groups.

CONCLUSIONS

Among STEMI patients undergoing PCI, early mTOR inhibition with everolimus did not reduce MI size or MVO at 30 days.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > Department of Clinical Research (DCR)

UniBE Contributor:

Heg, Dierik Hans, Branca, Mattia, Räber, Lorenz, Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0735-1097

Publisher:

Elsevier

Funders:

[4] Swiss National Science Foundation

Language:

English

Submitter:

Pubmed Import

Date Deposited:

05 Sep 2022 09:33

Last Modified:

20 Feb 2024 14:15

Publisher DOI:

10.1016/j.jacc.2022.08.747

PubMed ID:

36049557

Uncontrolled Keywords:

Acute myocardial infarction everolimus inflammation percutaneous coronary intervention

BORIS DOI:

10.48350/172616

URI:

https://boris.unibe.ch/id/eprint/172616

Actions (login required)

Edit item Edit item
Provide Feedback